Walt Tollison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Walt Tollison has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Felipe Kazmirczak
Allina Health Minneapolis Heart Institute, Abbott Northwestern Hospital, MN (F.K.).
2 shared publications- Jacob D. Sternbach
Lillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis (J.D.S., M.K., R.M.R., R.A.M., L.M.H.).
2 shared publications - Jenna B. Mendelson
Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN
2 shared publications - John P. Carney
University of Minnesota
2 shared publications - Kurt W. Prins
Gazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC
2 shared publications - Lynn M. Hartweck
Lillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis (J.D.S., M.K., R.M.R., R.A.M., L.M.H.).
2 shared publications
Latest Publications
- 6 November 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (11)
Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction
BACKGROUND: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multiomic evaluation of pulmonary artery banded pigs with differing degrees of right ventricular (RV) compromise. METHODS: Pulmonary artery banded pigs were stratified into mild and severe RVD groups based on RV ejection fraction (mild RVD, 38±4%; severe RVD, 20±8%). RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multiomic findings. RESULTS: Cardiac magnetic resonance imaging revealed progressive structural and functional alterations in mild and severe RVD pigs. Single-nucleus RNA sequencing demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, colocalization patterns in RV sections, and increased cardiomyocyte HIF1A (hypoxia-inducible factor 1 alpha) transcript expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared with severe RVD. Finally, integration of multiomic approaches identified activation of the ribotoxic stress response, impaired macrophage efferocytosis, and insufficient mitochondrial unfolded protein response as potential contributors to severe RVD. Multispecies comparison suggested that the ribotoxic stress response was the most conserved pathogenic response in RVD. CONCLUSIONS: Our multiomic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RVD. Future studies are needed to determine how engaging these pathways influences RV phenotypes.
- 6 November 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (11)
Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction
BACKGROUND: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multiomic evaluation of pulmonary artery banded pigs with differing degrees of right ventricular (RV) compromise. METHODS: Pulmonary artery banded pigs were stratified into mild and severe RVD groups based on RV ejection fraction (mild RVD, 38±4%; severe RVD, 20±8%). RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multiomic findings. RESULTS: Cardiac magnetic resonance imaging revealed progressive structural and functional alterations in mild and severe RVD pigs. Single-nucleus RNA sequencing demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, colocalization patterns in RV sections, and increased cardiomyocyte HIF1A (hypoxia-inducible factor 1 alpha) transcript expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared with severe RVD. Finally, integration of multiomic approaches identified activation of the ribotoxic stress response, impaired macrophage efferocytosis, and insufficient mitochondrial unfolded protein response as potential contributors to severe RVD. Multispecies comparison suggested that the ribotoxic stress response was the most conserved pathogenic response in RVD. CONCLUSIONS: Our multiomic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RVD. Future studies are needed to determine how engaging these pathways influences RV phenotypes.
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1231-1251
GP130 Antagonism Enhances Porcine RV Function
BACKGROUND: Right ventricular (RV) dysfunction is a risk factor for death in multiple cardiovascular diseases, but RV-enhancing therapies are lacking. Inhibition of GP130 (glycoprotein-130) signaling with the small molecule SC144 improves RV function in rodent RV dysfunction via anti-inflammatory and metabolic mechanisms. However, SC144’s efficacy and molecular effects in a translational large animal model of RV dysfunction are unknown. METHODS: Four-week-old castrated male pigs underwent pulmonary artery banding (PAB). After 3 weeks, PAB pigs were randomized into 2 groups (daily injections of SC144 [2.2 mg/kg, PAB-SC144, n=5] or vehicle [PAB-Veh, n=5] for 3 weeks). Five age-matched pigs served as controls. Cardiac magnetic resonance imaging quantified RV size/function. Right heart catheterization evaluated hemodynamics. Single-nucleus RNA sequencing delineated cell-type-specific changes between experimental groups. Electron microscopy evaluated RV mitochondrial morphology. Phosphoproteomics identified dysregulated RV kinases. Lipidomics and metabolomics quantified lipid species and metabolites in RV tissue and serum. Quantitative proteomics examined RV mitochondrial protein regulation. Confocal microscopy evaluated alterations in cardiomyocyte size, macrophage abundances, capillary density, and pericyte/endothelial cell localization patterns. RESULTS: SC144 significantly improved RV ejection fraction (control: 60±4%; PAB-Veh: 22±10%; PAB-SC144: 37±6%) without altering RV afterload. Single-nucleus RNA sequencing demonstrated that PAB-Veh pigs had lower cardiomyocyte and higher macrophage/lymphocyte/pericyte/endothelial cell abundances as compared with control, and many of these changes were blunted by SC144. Immunohistochemistry validated the reduction in RV macrophage infiltration by SC144. Both transcriptomics and proteomics approaches demonstrated that SC144 combatted the downregulation of cardiomyocyte metabolic genes/proteins induced by PAB. Kinome enrichment analysis suggested SC144 counteracted RV mTORC1 (mammalian target of rapamycin complex 1) activation. Correspondingly, SC144 rebalanced the RV autophagy pathway proteins and improved mitochondrial morphology. Integrated lipidomics, metabolomics, and proteomics analyses revealed that SC144 restored fatty acid metabolism. Finally, CellChat analysis, cardiomyocyte RNAseq analysis, and histological examination suggested SC144 rebalanced pericyte-endothelial cell interactions and blunted cardiomyocyte HIF1 (hypoxia-induced factor 1) activation. CONCLUSIONS: GP130 antagonism blunts RV immune cell infiltration, reduces proinflammatory gene programs in macrophages and lymphocytes, rebalances autophagy, and preserves fatty acid metabolism in cardiomyocytes, and restores endothelial cell and pericyte homeostasis to mitigate cardiomyocyte hypoxia and ultimately augments RV function.
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1231-1251
GP130 Antagonism Enhances Porcine RV Function
BACKGROUND: Right ventricular (RV) dysfunction is a risk factor for death in multiple cardiovascular diseases, but RV-enhancing therapies are lacking. Inhibition of GP130 (glycoprotein-130) signaling with the small molecule SC144 improves RV function in rodent RV dysfunction via anti-inflammatory and metabolic mechanisms. However, SC144’s efficacy and molecular effects in a translational large animal model of RV dysfunction are unknown. METHODS: Four-week-old castrated male pigs underwent pulmonary artery banding (PAB). After 3 weeks, PAB pigs were randomized into 2 groups (daily injections of SC144 [2.2 mg/kg, PAB-SC144, n=5] or vehicle [PAB-Veh, n=5] for 3 weeks). Five age-matched pigs served as controls. Cardiac magnetic resonance imaging quantified RV size/function. Right heart catheterization evaluated hemodynamics. Single-nucleus RNA sequencing delineated cell-type-specific changes between experimental groups. Electron microscopy evaluated RV mitochondrial morphology. Phosphoproteomics identified dysregulated RV kinases. Lipidomics and metabolomics quantified lipid species and metabolites in RV tissue and serum. Quantitative proteomics examined RV mitochondrial protein regulation. Confocal microscopy evaluated alterations in cardiomyocyte size, macrophage abundances, capillary density, and pericyte/endothelial cell localization patterns. RESULTS: SC144 significantly improved RV ejection fraction (control: 60±4%; PAB-Veh: 22±10%; PAB-SC144: 37±6%) without altering RV afterload. Single-nucleus RNA sequencing demonstrated that PAB-Veh pigs had lower cardiomyocyte and higher macrophage/lymphocyte/pericyte/endothelial cell abundances as compared with control, and many of these changes were blunted by SC144. Immunohistochemistry validated the reduction in RV macrophage infiltration by SC144. Both transcriptomics and proteomics approaches demonstrated that SC144 combatted the downregulation of cardiomyocyte metabolic genes/proteins induced by PAB. Kinome enrichment analysis suggested SC144 counteracted RV mTORC1 (mammalian target of rapamycin complex 1) activation. Correspondingly, SC144 rebalanced the RV autophagy pathway proteins and improved mitochondrial morphology. Integrated lipidomics, metabolomics, and proteomics analyses revealed that SC144 restored fatty acid metabolism. Finally, CellChat analysis, cardiomyocyte RNAseq analysis, and histological examination suggested SC144 rebalanced pericyte-endothelial cell interactions and blunted cardiomyocyte HIF1 (hypoxia-induced factor 1) activation. CONCLUSIONS: GP130 antagonism blunts RV immune cell infiltration, reduces proinflammatory gene programs in macrophages and lymphocytes, rebalances autophagy, and preserves fatty acid metabolism in cardiomyocytes, and restores endothelial cell and pericyte homeostasis to mitigate cardiomyocyte hypoxia and ultimately augments RV function.